Today: 8 June 2026
Charles Schwab stock slips despite $27.8 billion January inflows as investors brace for Fed minutes
15 February 2026
2 mins read

Charles Schwab stock slips despite $27.8 billion January inflows as investors brace for Fed minutes

New York, February 14, 2026, 17:31 EST — Markets have wrapped up for the day.

  • Schwab ended Friday down 1.4% at $93.72, trailing a nearly unchanged S&P 500.
  • The broker posted $27.8 billion in “core” net new assets for January. Transactional sweep cash, though, slipped down to $433.3 billion.
  • Markets will be closed Monday for Washington’s Birthday. Investors turn next to the Fed minutes on Feb. 18, with GDP and personal income figures due Feb. 20.

Charles Schwab (SCHW) finished Friday’s session off 1.4% at $93.72. This, despite the brokerage firm posting a strong kickoff to the year for customer inflows and trading volume. Wall Street’s shifting rate-cut bets drove the stock down heading into the long holiday break.

The monthly activity report carries weight—it’s among the rare regular glimpses investors get at Schwab’s client flows and cash balances outside of earnings. With rates bouncing around, updates like this can make a noticeable impact when they drop.

Schwab’s business model leaves it especially exposed to rate shifts. The company profits off the gap between returns on customer cash and what it pays them, plus earnings from loans secured by client portfolios. So, whenever Treasury yields or “sweep” cash rates move, those changes hit the stock directly.

Schwab’s January numbers showed “core” net new assets came in at $27.8 billion, filtering out major one-offs and certain CD flows. Total client assets posted an 18% jump year-over-year, reaching $12.15 trillion. New brokerage account openings for the month registered a 10% increase, bringing the total to 476,000. Transactional sweep cash dropped by $20.4 billion, landing at $433.3 billion—a move Schwab attributed to normal January trends. Schwab monthly activity release

Schwab lagged behind, with the S&P 500 inching up just 0.05% while the Nasdaq dipped 0.22% Friday. After the inflation numbers landed, CME’s FedWatch tool showed traders boosting the implied probability of a June rate cut to roughly 52%.

January’s CPI ticked up 0.2%, putting the annual rise at 2.4%—softer figures than economists had penciled in, according to a Reuters poll. Phil Orlando at Federated Hermes called the inflation read “better than expected.” Still, Josh Jamner of ClearBridge pointed to “price pressures percolating beneath the surface,” suggesting potential bumps ahead for the rate outlook. Reuters CPI report

Lower yields are a mixed bag for Schwab. They might buoy markets and nudge investors toward risk, but there’s a downside—those same yields squeeze the firm’s interest margin on client cash. The focus now is on January’s dip in sweep cash, as investors look for signs of whether it’s a blip or something more persistent.

Friday was also the record date for Schwab’s quarterly dividend, set for payment on Feb. 27, after the firm bumped up its payout to 32 cents per share. Shares went ex-dividend that same day—a technical move that sometimes weighs on the stock price.

Still, January’s update revealed a hefty drop in sweep cash—a critical earnings lever for Schwab. Should that cash pile keep shrinking, or if rocky markets put a lid on trading and new asset flows, the stock could struggle to claw back ground.

U.S. stock markets take a break for Washington’s Birthday on Monday, reopening Tuesday. For rate-sensitive stocks like Schwab, eyes are on the Fed’s January minutes due Feb. 18 and the revised dates for advance GDP and personal income data—now set for Feb. 20.

Stock Market Today

  • Micron's Stock Surges on Strong Memory Sector Outlook
    June 8, 2026, 9:57 AM EDT. Micron Technology's stock rebounded sharply, driven by renewed optimism in the memory chip sector. Analysts highlight that long-term supply agreements are improving memory companies' earnings prospects. These contracts, which secure steady revenue streams over extended periods, are seen as a positive development amid volatile market conditions. The upbeat sentiment reflects confidence that the memory trade remains robust despite past challenges. Investors are responding to these factors, signaling that the demand for memory chips continues to support Micron's growth potential.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next
Previous Story

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop